Breaking News

You are here » Indian-Commodity  :  Corporate  :  Aurobindo Pharma receives USFDA approval for Sevelamer Carbonate tablets

19-Jul2017

Aurobindo Pharma receives USFDA approval for Sevelamer Carbonate tablets

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture Sevelamer Carbonate tablets 800mg. Sevelamer Carbonate tablets, a therapeutic equivalent generic version of Genzyme's Renvela tablets. The product is being launched immediately.

Sevelamer Carbonate tablets is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis. The approved product has an estimated market size of $1.9 billion for the twelve months ending May 2017 according to IMS.

This is the 124th ANDA (including 21 tentative approvals) to be approved out of Unit VII formulation facility in Hyderabad, India used for manufacturing oral products. Aurobindo now has a total of 331 ANDA approvals (294 Final approvals including 16 from Aurolife Pharma LLC and 37 tentative approvals) from USFDA.




Related News

View all news

Sun Pharma receives Australian TGA approval for ILUMYA

Sun Pharmaceutical Industries has received the Australian Therapeutic Goods Administration (TGA) approval for its specialty product, ILUMYA (tildrakizumab) for the treatment of adults with moderate-to-severe......

TCS features as leader in Everest Group PEAK Matrix for F&A Digital Augmentation Suite

Tata Consultancy Services (TCS) has been positioned as a leader in the Everest Group PEAK Matrix for Finance and Accounting (F&A) Digital Augmentation Suite (DAS).Cited as a strength is the company's......

Tata Power bags 'GOLD' at CCQC 2018 Award

Tata Power has bagged three GOLD awards for excellent problem-solving capabilities and contribution of teams towards quality initiatives at Jojobera thermal power station at the recently held Chapter Convention......

Top News

View all news

Sun Pharma receives Australian TGA approval for ILUMYA

Sun Pharmaceutical Industries has received the Australian Therapeutic Goods Administration (TGA) approval for its specialty product, ILUMYA (tildrakizumab) for the treatment of adults with moderate-to-severe......

TCS features as leader in Everest Group PEAK Matrix for F&A Digital Augmentation Suite

Tata Consultancy Services (TCS) has been positioned as a leader in the Everest Group PEAK Matrix for Finance and Accounting (F&A) Digital Augmentation Suite (DAS).Cited as a strength is the company's......

Infosys enters into exclusive partnership with Trinity College

Infosys has entered into an exclusive partnership with Trinity College to create new educational programs that prepare liberal arts students and Infosys employees for the digital workplace of the future.......